UK markets closed
  • FTSE 100

    -4.48 (-0.08%)
  • FTSE 250

    +36.70 (+0.21%)
  • AIM

    -0.70 (-0.07%)

    +0.0051 (+0.46%)

    +0.0028 (+0.22%)

    +53.42 (+0.51%)
  • CMC Crypto 200

    +1.78 (+0.68%)
  • S&P 500

    -40.15 (-1.21%)
  • DOW

    -157.51 (-0.59%)

    -0.45 (-1.24%)

    +10.80 (+0.58%)
  • NIKKEI 225

    -354.81 (-1.52%)

    -479.18 (-1.95%)
  • DAX

    -41.59 (-0.36%)
  • CAC 40

    +24.57 (+0.54%)

Global Rectal Cancer Pipeline Report 2020: Therapeutics Assessment, Companies Involved, Dormant Projects, Landscape

Research and Markets
·4-min read

Dublin, Sept. 29, 2020 (GLOBE NEWSWIRE) -- The "Rectal Cancer - Pipeline Review, H2 2020" drug pipelines has been added to's offering.

Rectal Cancer - Pipeline Review, H2 2020, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Report Highlights

Rectal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews the key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 15, 8, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:


  • Rectal Cancer - Overview

  • Rectal Cancer - Therapeutics Development

Rectal Cancer - Therapeutics Assessment

Rectal Cancer - Companies Involved in Therapeutics Development

  • Rectal Cancer - Drug Profiles

Rectal Cancer - Dormant Projects

  • Rectal Cancer - Discontinued Products

  • Rectal Cancer - Product Development Milestones


Companies Mentioned

  • AD Pharmaceuticals Co Ltd

  • Advaxis Inc

  • Alkermes Plc

  • Amphivena Therapeutics Inc

  • Apexigen Inc

  • AptaBio Therapeutics Inc

  • AstraZeneca Plc

  • Biotts SA

  • CytomX Therapeutics Inc

  • Diverse Biotech Inc

  • Eisai Co Ltd

  • Eli Lilly and Co

  • Ellipses Pharma Ltd

  • GlaxoSmithKline Plc

  • Incyte Corp

  • Jiangsu Hengrui Medicine Co Ltd

  • Konruns Pharmaceutical Co Ltd

  • Luye Pharma Group Ltd

  • Merck KGaA

  • Millennium Pharmaceuticals Inc

  • Oncologie Inc

  • PDS Biotechnology Corp

  • Precigen Inc

  • Shanghai Haihe Biopharma Co Ltd

  • Stcube Inc

  • Taiho Oncology Inc

  • Teon Therapeutics Inc

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900